Evidence map›Paper›PMID 42448980›Full record

ArticleAnnals of surgical oncology2026

Improved Oncologic Outcomes with Trimodality Therapy for Radiation-Associated Angiosarcoma of the Breast.

Saskia J Leonard, Tanya Hoskin, Brittany L Siontis, Safia Ahmed, Tina J Hieken, James W Jakub, Christian Baum, Sarah Schrup, Jeffrey Johnson, Tiffany Sae-Kho and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Saskia J LeonardBreast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, MN, USA.
Tanya HoskinQHS - Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, USA.
Brittany L SiontisOncology, Mayo Clinic, Rochester, MN, USA.
Safia AhmedRadiation Oncology, Mayo Clinic, Rochester, MN, USA.
Tina J HiekenBreast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, MN, USA.
James W JakubDivision of Surgical Oncology, Mayo Clinic, Jacksonville, FL, USA.
Christian BaumDermatology, Mayo Clinic, Rochester, MN, USA.
Sarah SchrupMayo Clinic Graduate School, Rochester, MN, USA.
Jeffrey JohnsonBreast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, MN, USA.
Tiffany Sae-KhoBreast Imaging and Intervention, Mayo Clinic, Rochester, MN, USA.
Scott OkunoOncology, Mayo Clinic, Rochester, MN, USA.
Amy C DegnimBreast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, MN, USA. degnim.amy@mayo.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRadiation-associated angiosarcoma of the breast (RAASB) is a rare aggressive malignancy arising after breast irradiation. We previously reported that trimodality therapy showed high rates of pathologic complete response (pCR) and durable local control. Here we report an expanded cohort with longer follow-up to characterize the oncologic outcomes of this approach.

methodsWith IRB approval, we performed a retrospective review of newly diagnosed RAASB patients operated at Mayo Clinic in Rochester 2000-2025. Trimodality therapy was defined as sequential induction chemotherapy, preoperative concurrent chemoradiation, and wide surgical resection; Mono/Dual therapy consisted of surgery +/- chemotherapy. Clinical characteristics, treatments, and oncologic outcomes were abstracted. RFS was estimated using the Kaplan-Meier method and reported with 95% confidence intervals (CI).

resultsForty-three patients (median age 68 years [40-80]) were included; 24 Trimodality therapy and 19 Mono/Dual therapy. Age and extent of presenting disease was similar between the Trimodality and Mono/Dual therapy groups. All Trimodality patients received chemotherapy, chemoradiation, and wide resection with flap closure. Among Mono/Dual patients, none had radiation, 47% had chemotherapy, and 68% had wide resection, with flap closure in 58%. Eight-year recurrence free survival was superior in the Trimodality group at 96% [95% CI 87-100%], versus 50% [95% CI 30-86%] in the Mono/Dual group, p = 0.002. Eight-year overall survival was also superior in the Trimodality group at 94% [95% CI 84-100%], versus 65% [95% CI 45-95%] in the Mono/Dual group, p = 0.047.

conclusionsTrimodality therapy for RAASB demonstrates high rates of pCR, local control, and survival.

Indexed as

Breast NeoplasmsChemoradiotherapyHemangiosarcomaMastectomyNeoplasm Recurrence, LocalNeoplasms, Radiation-InducedAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyFemaleFollow-Up StudiesHumansInduction ChemotherapyMiddle AgedAngiosarcomaBreast irradiationRadiation-associatedTrimodality therapy

Identifiers

PMID42448980

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.